1,4-bis[(4-ethoxybenzensulfonyl)amino]naphthalene

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1,4-bis[(4-ethoxybenzensulfonyl)amino]naphthalene
• 英文别名: N,N′-(naphthalene-1,4-diyl)bis(4-ethoxybenzenesulfonamide)；4-ethoxy-N-[4-[(4-ethoxyphenyl)sulfonylamino]naphthalen-1-yl]benzenesulfonamide
• 化学式: C₂₆H₂₆N₂O₆S₂
• 分子量: 526.634
• InChiKey: GVQLOWNGYDYVQC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  36
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  128
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  1,4-bis[(4-ethoxybenzensulfonyl)amino]naphthalene 在 ammonium cerium (IV) nitrate 作用下， 以 乙腈 为溶剂， 反应 0.3h， 以89%的产率得到N,N′-((1Z,4Z)-naphthalene-1,4-diylidene)bis(4-ethoxybenzenesulfonamide)
  参考文献：
  名称：

  A Comparative Assessment Study of Known Small-Molecule Keap1−Nrf2 Protein–Protein Interaction Inhibitors: Chemical Synthesis, Binding Properties, and Cellular Activity

  摘要：

  Inhibiting the protein-protein interaction (PPI) between the transcription factor Nrf2 and its repressor protein Keap1 has emerged as a promising strategy to target oxidative stress in diseases, including central nervous system (CNS) disorders. Numerous non-covalent small-molecule Keap1-Nrf2 PPI inhibitors have been reported to date, but many feature suboptimal physicochemical properties for permeating the blood brain barrier, while others contain problematic structural moieties. Here, we present the first side-by-side assessment of all reported Keap1-Nrf2 PPI inhibitor classes using fluorescence polarization, thermal shift assay, and surface plasmon resonance-and further evaluate the compounds in an NQO1 induction cell assay and in counter tests for nonspecific activities. Surprisingly, half of the compounds were inactive or deviated substantially from reported activities, while we confirm the cross-assay activities for others. Through this study, we have identified the most promising Keap1-Nrf2 inhibitors that can serve as pharmacological probes or starting points for developing CNS-active Keap1 inhibitors.

  DOI：

  10.1021/acs.jmedchem.9b00723
• 作为产物：
  描述：

  1-氨基-4-硝基萘 在 吡啶 、 5%-palladium/activated carbon 、 氢气 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 4.67h， 生成 1,4-bis[(4-ethoxybenzensulfonyl)amino]naphthalene
  参考文献：
  名称：

  Keap1-磷酸化的p62和Keap1-Nrf2蛋白-蛋白相互作用抑制剂的合成及其抑制活性。

  摘要：

  Keap1-Nrf2系统不仅参与生物防御，而且还参与恶性进展和化学抗药性。在多种癌症中高度表达的泛素结合蛋白p62 / Sqstm1（p62）与Nrf2竞争Keap1结合，从而激活Nrf2介导的基因表达和癌细胞的存活。我们先前已经确定了Keap1-磷酸化p62（p-p62）蛋白质-蛋白质相互作用（PPI）的抑制剂，即丙酮基萘衍生物K67。在这项研究中，我们为萘环的C-2位置上的各种侧链的K67及其衍生物建立了简便的合成路线。K67在抑制Keap1-p-p62方面具有很高的选择性。其他衍生物显示出有效的Keap1-Nrf2和Keap1-p-p62 PPI抑制活性，

  DOI：

  10.1016/j.bmcl.2016.10.083

文献信息

• Synthesis of Keap1-phosphorylated p62 and Keap1-Nrf2 protein-protein interaction inhibitors and their inhibitory activity
  作者：Daisuke Yasuda、Mao Nakajima、Akihiro Yuasa、Rika Obata、Kyoko Takahashi、Tomoyuki Ohe、Yoshinobu Ichimura、Masaaki Komatsu、Masayuki Yamamoto、Riyo Imamura、Hirotatsu Kojima、Takayoshi Okabe、Tetsuo Nagano、Tadahiko Mashino

  DOI：10.1016/j.bmcl.2016.10.083

  日期：2016.12

  cancers, competes with Nrf2 for Keap1 binding, leading to activation of Nrf2-mediated gene expression and survival of cancer cells. We had previously identified an inhibitor for the Keap1-phosphorylated-p62 (p-p62) protein-protein interaction (PPI), the acetonyl naphthalene derivative K67. In this study, we established facile synthetic routes for K67 and derivatives with various side chains on the C-2

  Keap1-Nrf2系统不仅参与生物防御，而且还参与恶性进展和化学抗药性。在多种癌症中高度表达的泛素结合蛋白p62 / Sqstm1（p62）与Nrf2竞争Keap1结合，从而激活Nrf2介导的基因表达和癌细胞的存活。我们先前已经确定了Keap1-磷酸化p62（p-p62）蛋白质-蛋白质相互作用（PPI）的抑制剂，即丙酮基萘衍生物K67。在这项研究中，我们为萘环的C-2位置上的各种侧链的K67及其衍生物建立了简便的合成路线。K67在抑制Keap1-p-p62方面具有很高的选择性。其他衍生物显示出有效的Keap1-Nrf2和Keap1-p-p62 PPI抑制活性，
• Discovery of benzo[g]indoles as a novel class of non-covalent Keap1-Nrf2 protein-protein interaction inhibitor
  作者：Daisuke Yasuda、Akihiro Yuasa、Rika Obata、Mao Nakajima、Kyoko Takahashi、Tomoyuki Ohe、Yoshinobu Ichimura、Masaaki Komatsu、Masayuki Yamamoto、Riyo Imamura、Hirotatsu Kojima、Takayoshi Okabe、Tetsuo Nagano、Tadahiko Mashino

  DOI：10.1016/j.bmcl.2017.10.008

  日期：2017.11

  The Keap1-Nrf2 system is an attractive target for drug discovery regarding various unmet medical needs. Only covalent inhibitors for protein-protein interaction (PPI) between Keap1 and Nrf2 to activate Nrf2 have been approved or are under clinical trials, but such electrophilic compounds lack selectivity. Therefore, specific non-covalent Keap1-Nrf2 PPI inhibitors are expected to be safer Nrf2 activators. We found a novel class of non-covalent Keap1-Nrf2 PPI inhibitor that has a benzo[g]indole skeleton and an indole-3-hydroxamic acid moiety and that exhibits significant PPI inhibitory activity. Additionally, the benzo[g]indole-3-carbohydrazide derivatives were newly prepared. The benzo[g]indole derivatives showed a stronger Keap1-Nrf2 PPI inhibitory activity than Cpd16, a previously reported non-covalent PPI inhibitor. Moreover, most of the PPI inhibitors showed a high metabolic stability in a human microsome system with a low cytotoxicity against HepG2 cell lines, which suggests that novel benzo[g]indole-type Keap1-Nrf2 PPI inhibitors are expected to be biological tools or lead compounds for Nrf2 activators. (C) 2017 Elsevier Ltd. All rights reserved.
• A Comparative Assessment Study of Known Small-Molecule Keap1−Nrf2 Protein–Protein Interaction Inhibitors: Chemical Synthesis, Binding Properties, and Cellular Activity
  作者：Kim T. Tran、Jakob S. Pallesen、Sara M. Ø. Solbak、Dilip Narayanan、Amina Baig、Jie Zang、Alejandro Aguayo-Orozco、Rosa M. C. Carmona、Anthony D. Garcia、Anders Bach

  DOI：10.1021/acs.jmedchem.9b00723

  日期：2019.9.12

  Inhibiting the protein-protein interaction (PPI) between the transcription factor Nrf2 and its repressor protein Keap1 has emerged as a promising strategy to target oxidative stress in diseases, including central nervous system (CNS) disorders. Numerous non-covalent small-molecule Keap1-Nrf2 PPI inhibitors have been reported to date, but many feature suboptimal physicochemical properties for permeating the blood brain barrier, while others contain problematic structural moieties. Here, we present the first side-by-side assessment of all reported Keap1-Nrf2 PPI inhibitor classes using fluorescence polarization, thermal shift assay, and surface plasmon resonance-and further evaluate the compounds in an NQO1 induction cell assay and in counter tests for nonspecific activities. Surprisingly, half of the compounds were inactive or deviated substantially from reported activities, while we confirm the cross-assay activities for others. Through this study, we have identified the most promising Keap1-Nrf2 inhibitors that can serve as pharmacological probes or starting points for developing CNS-active Keap1 inhibitors.
• Inhibitors of the protein–protein interaction between phosphorylated p62 and Keap1 attenuate chemoresistance in a human hepatocellular carcinoma cell line
  作者：Daisuke Yasuda、Tomoyuki Ohe、Kyoko Takahashi、Riyo Imamura、Hirotatsu Kojima、Takayoshi Okabe、Yoshinobu Ichimura、Masaaki Komatsu、Masayuki Yamamoto、Tetsuo Nagano、Tadahiko Mashino

  DOI：10.1080/10715762.2020.1732955

  日期：2020.12.1

  overexpressed in several HCC cell lines, such as Huh-1 cells. Phosphorylated p62 (p-p62) inhibits the protein–protein interaction (PPI) between Keap1 and Nrf2, resulting in the Nrf2 overactivation that causes drug resistance. We have found a unique Nrf2 inactivator, named K67, that inhibited the PPI between Keap1 and p-p62 and attenuated sorafenib resistance in Huh-1 cells. Herein, we designed and synthesised

  摘要 对抗癌药物的耐药性一直是开发治疗方法和降低医疗成本的障碍。虽然索拉非尼用于治疗人类肝细胞癌 (HCC)，但耐药性限制了其疗效。p62 是一种多功能蛋白，在几种 HCC 细胞系（例如 Huh-1 细胞）中过表达。磷酸化的 p62 ( p -p62) 抑制 Keap1 和 Nrf2 之间的蛋白质-蛋白质相互作用 (PPI)，导致 Nrf2 过度激活，从而导致耐药性。我们发现了一种独特的 Nrf2 灭活剂，名为 K67，它抑制了 Keap1 和p之间的 PPI-p62 并减弱 Huh-1 细胞中的索拉非尼耐药性。在此，我们通过修饰 K67 的两个苯磺酰基的 4 位取代基，设计并合成了新型 K67 衍生物。尽管这些新衍生物抑制 Keap1- p- p62 PPI 的水平与 K67 相当或更弱，但异丙氧基衍生物比 K67 更大程度地增强了 Huh-1 细胞对索拉非尼的敏感性，而对细胞活力没有任何影响。